Epitalon
Synthetic Pineal Tetrapeptide · Telomerase Activator
Epitalon is a synthetic tetrapeptide developed by Russian scientist Vladimir Khavinson with 35+ years of research. It activates telomerase at extremely low concentrations to maintain telomere length, stimulates melatonin production, and modulates gene expression through epigenetic mechanisms.
Overview
Epitalon is a synthetic tetrapeptide developed by Russian scientist Vladimir Khavinson with 35+ years of research. It activates telomerase at extremely low concentrations to maintain telomere length, stimulates melatonin production, and modulates gene expression through epigenetic mechanisms.
Activates telomerase at extremely low concentrations (10⁻¹⁷ to 10⁻¹⁵ M) to maintain telomere length, stimulates melatonin production from the pineal gland, and modulates gene expression through epigenetic mechanisms.
Research indications
What the compound has been studied for, grouped by body system. Effect size is the reported magnitude where it was measured — not a recommendation.
Activates telomerase at microgram doses to extend telomeres and cellular replicative lifespan.
Reverses aging markers and improves mitochondrial function at the cellular level.
Animal studies show 25-33% lifespan increases using 30-40mcg/kg doses.
Restores pineal gland function and circadian melatonin rhythm in elderly.
Supports new neuron formation at nanogram concentrations.
90% response rate for retinal degeneration at 5mcg per eye dosing.
Supports thymus gland regeneration for improved immune function.
Enhanced immune surveillance and countering of immunosenescence.
A large effect in a weak study and a small effect in a strong one are different things. Effect size is never evidence of use in people.
- Class
- Tetrapeptide
- Chain length
- 4 residues
- Molecular weight
- 390.35 Da
- Typical dose
- 100-500mcg per injection
- Frequency
- Once daily for 10-20 consecutive days
- Cycle length
- 10-20 days per cycle
- Storage
- Lyophilized: 2-8°C refrigerated; Reconstituted: 2-8°C refrigerated, use within 30 days
Molecular data
- Type
- Tetrapeptide
- Molecular weight
- 390.35 Da
- Chain length
- 4 residues
AEDGDosing reference
Doses reported in the literature and by suppliers. These are a record of what has been used in research — reference, never instruction.
| Context | Route | Amount | Frequency |
|---|---|---|---|
| Standard anti-aging | SubQ | 200-500mcg | 1x daily for 10-20 days |
| Conservative start | SubQ | 100mcg | 1x daily for 10-20 days |
| Russian clinical equivalent | SubQ | 300mcg | 1x daily for 10-20 days |
| Ultra-low dose | SubQ | 50mcg | 1x daily for 10-20 days |
| Nasal administration | Nasal spray | 1-2mg daily (corrected from traditional 5mg) | 1x daily for 10-20 days |
| Oral administration | Oral | 2-3mg | 2x daily for 10-20 days |
Interactions
Both work through pineal pathways; may enhance circadian rhythm effects.
Enhanced immunomodulation - commonly combined in Russian protocols.
Different anti-aging pathways; complementary mechanisms.
Different axis activation; no known interactions.
Different regenerative mechanisms.
Both are neuroprotective; monitor for cumulative effects.
Different neurocognitive focus.
Telomerase activation may theoretically affect malignancy; avoid with active cancer.
Quality checklist
- ✓White to off-white lyophilized powder
- ✓Clear, colorless solution when reconstituted
- ✓Certificate of analysis available (>98% purity)
- ✓Medical-grade pharmaceutical appearance
- ✓Proper cold-chain shipping
- !Widespread dosing misinformation exists
- !Many sources recommend 5-10mg based on translation errors
- !Original research demonstrates microgram efficacy
- !Verify supplier credentials carefully
- ×Yellow or discolored powder (degradation)
- ×Cloudy solution after mixing (contamination)
- ×Missing or questionable sourcing documentation
What to expect
Safety
- Generally well-tolerated with minimal side effects
- Mild injection site reactions
- Vivid dreams (melatonin-related)
- Possible mild digestive upset (oral route)
- Signs of allergic reaction
- Persistent injection site inflammation
- New or changing moles (monitor skin)
- Cancer diagnosis (discontinue immediately)
- Unusual fatigue or weakness
- Active malignancy (telomerase activation concern)
- Chronic sinusitis (nasal route)
- Known peptide allergies
- Pregnancy or breastfeeding
FAQ
What's the correct Epitalon dosage—why do some sources recommend 5-10mg versus 0.5-1mg?
Peer-reviewed human clinical trials show efficacy at 0.5-1mg daily, while many community protocols recommend 5-10mg based on what appears to be translation errors from animal studies. Original research demonstrates microgram-level activation of telomerase, making lower doses research-supported. Higher doses lack human validation and are significantly more expensive.
Does Epitalon really extend lifespan or is that just animal studies?
Animal studies show 25-33% lifespan extension with Epitalon, and a 6-8 year clinical trial of 266 elderly subjects found a 1.6-1.8 fold mortality reduction with Epithalamin. While impressive, human lifespan extension claims remain theoretical. Effects on cellular aging markers like telomere length are better documented than actual longevity in humans.
Should I worry about Epitalon and cancer risk given telomerase activation?
Telomerase activation theoretically carries cancer risk, which is why Epitalon is contraindicated in active malignancy. However, 35+ years of research shows no increased cancer incidence in clinical trials. The key distinction: Epitalon activates telomerase in normal cells while cancer cells already have telomerase; the mechanism appears selective for aging cells.
How long after an Epitalon cycle do benefits persist?
Effects persist for months after a 10-20 day cycle due to epigenetic changes in gene expression and sustained telomerase activity. Many users repeat cycles 2-3 times yearly with 4-6 month breaks, allowing the body to maintain benefits from each cycle while avoiding continuous stimulation.
References
- 1Synthetic tetrapeptide epitalon restores disturbed neuroendocrine regulation in senescent monkeysKhavinson VKh, Goncharova ND, Lapin BA · Neuroendocrinology Letters · 2001
Epitalon significantly stimulated melatonin synthesis in senescent monkeys during evening hours, normalizing circadian rhythm of cortisol secretion and restoring neuroendocrine regulation.
reviewPubMed 11524632 ↗ - 2Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosaKhavinson VKh, Razumovsky MI, Trofimova SV, Grigoryan RA, Kharitonova OA · Neuroendocrinology Letters · 2002
Epitalon therapy in patients with degenerative retinal lesions resulted in positive clinical effect in 90% of cases, intensifying bioelectric and functional activity of retina due to preservation of morphological structure.
human-pilotPubMed 12195242 ↗ - 3Epithalon peptide induces telomerase activity and telomere elongation in human somatic cellsKhavinson VKh, Bondarev IE, Butyugov AA · Bulletin of Experimental Biology and Medicine · 2003
Addition of epithalon to telomerase-negative human fetal fibroblast culture induced expression of catalytic subunit (hTERT), enzymatic activity of telomerase, and telomere elongation. Extended replicative lifespan of cells.
in-vitroPubMed 12937682 ↗ - 4Peptides of pineal gland and thymus prolong human lifeKhavinson VKh, Morozov VG · Neuroendocrinology Letters · 2003
Clinical trial of 266 elderly subjects over 6-8 years: Epithalamin reduced mortality 1.6-1.8 fold. Combined Thymalin + Epithalamin treatment for 6 years reduced mortality 4.1-fold vs control with improved cardiovascular and immune parameters.
reviewPubMed 14523363 ↗ - 5Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR miceAnisimov VN, Khavinson VKh, Popovich IG, Zabezhinski MA, Alimova IN, Rosenfeld SV, Zavarzina NY, Semenchenko AV, Yashin AI · Biogerontology · 2003
Epitalon injected from 3 months until natural death increased maximum lifespan by 12.3% and last 10% survivors by 13.3%. Slowed age-related estrous function decline and reduced chromosome aberrations by 17.1%. Inhibited leukemia development 6-fold.
animalPubMed 14501183 ↗ - 6AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic MechanismKhavinson VKh, Diomede F, Mironova E, Linkova N, Trofimova S, Trubiani O, Marconi GD, Paiushina O · Molecules · 2020
AEDG peptide increased neurogenic differentiation markers (Nestin, GAP43, β-Tubulin III, Doublecortin) 1.6-1.8 fold in human gingival mesenchymal stem cells. Molecular modelling showed preferential binding with H1/6 and H1/3 histones, suggesting epigenetic regulation.
reviewPubMed 32019204 ↗